Full-Time
Senior Clinical Research Associate 2
Sponsor Dedicated
Posted on 6/13/2026
Fortrea
10,001+ employees
Global CRO providing Phase I-IV trials
No salary listed
Munich, Germany
Remote
Remote within Germany; willingness to travel is required.
Bachelor's
 Biology & Biotech (1) |
|---|
Get referred to Fortrea
See people who can refer or advise you
- A bachelor's degree in Life Sciences or equivalent experience.
- At least 5 years of experience in clinical research, including site monitoring or site management.
- Proven experience in oncology, ophthalmology, gene therapy, or a similar therapeutic area.
- Strong knowledge of ICH-GCP, regulatory requirements, and clinical trial processes.
- Proficiency in German and English.
- Willingness to travel.
- Act as the primary contact for assigned clinical trial sites and build strong, collaborative relationships.
- Manage the site lifecycle from start-up through monitoring and close-out, ensuring delivery to timelines and quality standards.
- Conduct on-site and remote monitoring, identify risks, and drive timely issue resolution.
- Ensure compliance with the study protocol, ICH-GCP, and local regulatory requirements.
- Oversee site performance, including data quality, recruitment, training, and documentation completeness.
- Support study execution, including feasibility, site activation, investigator meetings, and audit readiness.
- Collaborate cross-functionally to implement site strategies and ensure successful trial delivery.
Fortrea is a global contract research organization that provides clinical development services for the life sciences industry. It offers full service, functional service, and hybrid outsourcing models across Phase I–IV trials, clinical pharmacology, and consulting, serving biotech, biopharma, medical devices, and diagnostics. Its work is delivered through a network of investigators and specialized teams in approximately 100 countries, supporting trial design, execution, data management, and regulatory compliance. Fortrea’s approach combines its legacy experience from Covance and Labcorp with a pureplay CRO model to deliver fit-for-purpose solutions and agile project delivery. This positions it to manage trials across more than 20 therapeutic areas with scientific rigor and operational excellence. The company aims to bring predictability to clinical trial execution and help clients turn research ideas into real-world outcomes.
Company Size
10,001+
Company Stage
IPO
Headquarters
Durham, North Carolina
Founded
2023
Get referred to Fortrea
See people who can refer or advise you
Simplify's Take
What believers are saying
- Q2 2026 revenue reached $678.2 million, beating expectations and lifting guidance.
- Fortrea raised 2026 revenue guidance to $2.55 billion-$2.65 billion in July 2026.
- Cost optimization targets of $70-80 million gross support margin recovery in 2026.
What critics are saying
- The 2025 shareholder class action remains active after Fortrea's January 2026 dismissal motion.
- Ongoing 2024 and 2025 restructuring through 2026 signals continued redundant-position eliminations.
- Revenue still declined 4.5% in Q2 2026, exposing weak underlying growth.
What makes Fortrea unique
- Fortrea's July 2026 book-to-bill stayed 1.12x, signaling durable demand.
- September 2026 Worldwide early-phase acquisition adds Austin, San Antonio, and Pflugerville capacity.
- Integrated Phases I-IV platform now spans first-in-human studies through post-approval evidence generation.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
Dental Insurance
Vision Insurance
Life Insurance
Disability Insurance
401(k) Retirement Plan
401(k) Company Match
Unlimited Paid Time Off
Paid Vacation
Growth & Insights and Company News
6 month growth
↑ 27%1 year growth
↑ 27%2 year growth
↑ 27%Fortrea's $45M acquisition of Worldwide Clinical Trials' early-phase division adds a 60,000 sq ft bioanalytical lab. Here's what it means for Phase I site…
Fortrea acquires the clinical pharmacology unit and bioanalytical laboratory activities of Worldwide Clinical Trials. This acquisition brings dedicated bioanalytical expertise and increased capacity to Fortrea's early clinical development network as Worldwide continues its strategy to strengthen its clinical development activities, therapeutic leadership, and presence in high-growth markets.
Fortrea to acquire clinical pharmacology unit and bioanalytical laboratory operations from Worldwide Clinical Trials. September 02, 2026 Adds dedicated bioanalytical capabilities and expanded capacity to Fortrea's early clinical development network as Worldwide advances its strategy to scale clinical development, therapeutic leadership and high-growth markets Highlights * Fortrea enters into a definitive agreement to acquire the Early Phase Services division of Worldwide Clinical Trials * Includes a 60,000 sq. ft. GLP bioanalytical lab in Austin; a 200-bed GCP-compliant clinical pharmacology unit in San Antonio; and a biospecimen storage facility in Pflugerville, Texas * Enables integrated execution of early-phase studies with large and small molecule bioanalytical capabilities, enhancing Fortrea's ability to deliver faster, more integrated early clinical development solutions for simple and complex clinical studies * Strengthens Fortrea's end-to-end clinical development platform, supporting customers from first-in-human studies through Phase IV and post-approval evidence generation * Supports Fortrea's growth strategy through expanded scientific capabilities, increased early clinical development capacity and enhanced ability to create long-term value for shareholders * Supports Worldwide Clinical Trials' existing rapid global growth across oncology, neuroscience, internal medicine, and rare disease
Fortrea, a contract research organisation spun off from Labcorp in 2023, reported Q2 revenues of $678.2 million, down 4.5% year-on-year but exceeding analyst expectations by 4.7%. The company helps pharmaceutical, biotech, and medical device companies develop products through clinical trials and support services. Chief executive officer Anshul Thakral said the results reflected continued progress against the company's strategy and disciplined execution. The quarter saw Fortrea beat earnings per share estimates, with full-year revenue guidance surpassing analyst expectations. Among the eight drug development inputs and services stocks tracked, revenues collectively beat consensus estimates by 4.1%. Despite posting the slowest revenue growth in the group, the sector's share prices rose 12.6% on average. Fortrea's stock fell 5.7% following the results and currently trades at $19.52.
Fortrea Holdings reported second-quarter revenue of $678.2 million, exceeding analyst estimates by 4.7% despite a 4.5% year-on-year decline. The clinical research company's adjusted earnings per share of $0.23 beat consensus estimates by 27.2%. The company raised its full-year revenue guidance to $2.66 billion at the midpoint, up 2.1% from previous guidance and 1.8% above analyst expectations. Full-year EBITDA guidance of $212.5 million also surpassed estimates. Operating margin improved significantly to 2.2%, compared to negative 46.5% in the same quarter last year. CEO Anshul Thakral said the results reflect continued progress against the company's strategy. However, analysts project revenue to remain flat over the next 12 months, suggesting limited near-term growth prospects.